

HALOZYME THERAPEUTICS INC

Form 8-K

December 12, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

December 8, 2011

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-32335

88-0488686

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

11388 Sorrento Valley Road, San Diego,
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

858-794-8889

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

(a) On December 8, 2011, the Board of Directors of Halozyme Therapeutics, Inc. (the "Company") adopted amendments to the Bylaws of the Company (i) to permit stockholders holding 50% of the outstanding shares of the Company to call a special meeting of stockholders, and (ii) to allow stockholders to act by written consent. Prior to the amendment of the Bylaws, only the Board of Directors or the Chairman of the Board could call a special meeting of stockholders and any action required or permitted to be taken by the stockholders of the Company could only be effected at a duly called annual or special meeting of stockholders. The preceding summary of the changes to the Bylaws is qualified in its entirety by reference to the Bylaws, as amended, which are filed as an exhibit to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

Exhibit Description

3.1 Bylaws, as amended

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HALOZYME THERAPEUTICS, INC.

December 12, 2011

By: *Jean Liu*

Name: Jean Liu

Title: Vice President, General Counsel and Secretary

Top of the Form

Exhibit Index

Exhibit No.	Description
3.1	Bylaws, as amended